Pharmacologic Treatment of Osteogenesis Imperfecta: New Agents and their Potential Implications for Osteogenesis Imperfecta

Eric S. Orwoll, Elizabeth Martin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Current pharmacologic treatment of osteogenesis imperfecta (OI) consists of agents studied in and developed for use in osteoporosis. New agents under study for use in osteoporosis may also benefit patients with OI. In this chapter we review recommendations for current dietary supplements and the potential of several new anabolic and anti-resorptive agents for use in OI, including recombinant parathyroid hormone, sclerostin antibodies, strontium ranelate, RANK-ligand inhibitors, and cathepsin K inhibitors. While many of these agents may prove beneficial to patients with OI, optimal therapies for the future will target the specific collagen mutations underlying the disorder.

Original languageEnglish (US)
Title of host publicationOsteogenesis Imperfecta
Subtitle of host publicationA Translational Approach to Brittle Bone Disease
PublisherElsevier Inc.
Pages519-525
Number of pages7
ISBN (Print)9780123971654
DOIs
StatePublished - Sep 1 2013

Keywords

  • Bisphosphonates
  • Bone remodeling
  • Cathepsin K
  • Parathyroid hormone
  • Pharmacology
  • RANK ligand
  • Sclerostin
  • Vitamin D
  • Wnt

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Fingerprint Dive into the research topics of 'Pharmacologic Treatment of Osteogenesis Imperfecta: New Agents and their Potential Implications for Osteogenesis Imperfecta'. Together they form a unique fingerprint.

  • Cite this

    Orwoll, E. S., & Martin, E. (2013). Pharmacologic Treatment of Osteogenesis Imperfecta: New Agents and their Potential Implications for Osteogenesis Imperfecta. In Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease (pp. 519-525). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-397165-4.00056-3